36Kr reports that the Doubao App is conducting a limited test of its ride-hailing service in Beijing and Hangzhou, with Cao Cao Mobility providing the service. Separately, Insilico Medicine has partnered with SK Biopharmaceuticals to discover novel drug candidates for neuroimmune diseases affecting the central nervous system, with Insilico eligible for up to $18 million in upfront and milestone payments, and potential total deal value exceeding $2.5 billion. AI
IMPACT The Doubao App's ride-hailing test may indicate a trend of AI applications expanding into daily services, while the Insilico Medicine partnership highlights AI's role in accelerating drug discovery.
RANK_REASON The cluster contains a limited test of a ride-hailing service and a drug discovery partnership, neither of which rise to the level of significant industry news.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
